Frankfurt
01.06.26 | 08:30
0,069 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Klaria Pharma Holding AB: Klaria Interim Report Q1 2026 | 111 | GlobeNewswire (Europe) | Klaria Interim Report Q1 2026 1 January - 31 March
Summary of the interim reportFirst quarter of 2026 The group in total - Net sales 0.1 MSEK (9.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| Do | KLARIA PHARMA HOLDING AB: Klaria adjusts annual report release date | 1 | Cision News | ||
| 25.05. | Klaria Pharma Holding AB: Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ) | 242 | GlobeNewswire (Europe) | With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959-2917, are hereby invited to attend the Annual General... ► Artikel lesen | |
| 22.05. | KLARIA PHARMA HOLDING AB: Klaria postpones interim Q1 report | 1 | Cision News | ||
| 21.05. | KLARIA PHARMA HOLDING AB: Klaria postpones publication of the annual report | 2 | Cision News | ||
| 23.04. | Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.04. | KLARIA PHARMA HOLDING AB: Annula Genernal Meeting Date Change: Klaria Pharma Holding (publ) | 2 | Cision News | ||
| 19.03. | Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 19.03. | Klaria Pharma Holding AB: Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 312 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting... ► Artikel lesen | |
| 02.03. | Klaria Pharma Holding AB (publ) Summons to Extraordinary General Meeting | 2 | Cision News | ||
| 20.02. | Klaria Pharma Holding AB: Klaria Year-End Report | 661 | GlobeNewswire (Europe) | Klaria Year-End Report Q4 2025
1 January-31 December 2025
SummaryFourth quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 23.12.25 | Klaria Pharma Holding AB: Klaria accelerates its business development work in collaboration with BDO | 808 | GlobeNewswire (Europe) | With Klaria's product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP's UK Life Sciences & Healthcare M&A team... ► Artikel lesen | |
| 17.12.25 | Klaria Pharma Holding AB: Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application | 207 | GlobeNewswire (Europe) | Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.... ► Artikel lesen | |
| 26.11.25 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2025 | 228 | GlobeNewswire (Europe) | Klaria Interim Report
1 July - 30 September 2025
Summary of the interim reportThird quarter of 2025
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.08.25 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2025 | 349 | GlobeNewswire (Europe) | Klaria interim report
1 April-30 June 2025
Summary of the interim reportSecond quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses... ► Artikel lesen | |
| 18.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.06.2025 | 823 | Xetra Newsboard | Das Instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 18.06.2025 The instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY is traded ex capital... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 47,310 | +0,17 % | BioNTech SE: Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs | Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs... ► Artikel lesen | |
| DERMAPHARM | 47,450 | +0,64 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Dermapharm von 34 auf 44 Euro angehoben, aber die Einstufung auf "Hold" belassen. Die Profitabilität des Spezialisten für... ► Artikel lesen | |
| INCYTE | 81,90 | -0,32 % | Die zulassungsrelevante frontMIND-Studie von Incyte zeigte, dass die Kombination mit Tafasitamab (Monjuvi/Minjuvi) das progressionsfreie Überleben signifikant verlängerte und das Risiko eines Krankheitsfortschritts oder des Todes bei Patienten... | Die Phase-3-Studie frontMIND untersuchte Tafasitamab (Monjuvi/Minjuvi) und Lenalidomid zusätzlich zu R-CHOP, dem aktuellen Standard der Behandlung, im Vergleich zu R-CHOP allein bei Patienten... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 7,070 | 0,00 % | Green Thumb Industries: Marijuana Meme Stock or Dream Stock? | ||
| CHRISTINA LAKE CANNABIS | 0,010 | -28,57 % | Christina Lake Cannabis Corp: Christina Lake investor Milia acquires 5.03M shares | ||
| PSYCHED WELLNESS | 0,005 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector | Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,840 | +0,51 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| OPKO HEALTH | 1,200 | -0,83 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| COSMO | 83,00 | +0,48 % | Cosmo Metals completes Kanowna Gold diamond drilling phase | ||
| GREENRISE GLOBAL BRANDS | 0,005 | -100,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,030 | 0,00 % | BetterLife Pharma Inc. - 20-F, Annual and transition report of foreign private issuers | ||
| MEDIPHARM LABS | 0,050 | +3,09 % | Medipharm Labs Corp: Medipharm Labs reminds holders of June 17 AGSM | ||
| PROMINO NUTRITIONAL SCIENCES | 0,018 | 0,00 % | Promino Nutritional Sciences Inc (2): Promino launches Drink Rej website | ||
| ADDEX THERAPEUTICS | 0,046 | 0,00 % | Addex Therapeutics: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update | GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury... ► Artikel lesen |
KLARIA PHARMA HOLDING AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,069 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.